Anand Rathi recommends BUY on Jyothy Laboratories

jyothiJyothy Laboratories – Well-groomed; Buy

 

Key takeaways from management interaction

 

Volume upturn, overall. During 1HFY15, Jyothy Labs reported robust, 16%  yoy,  revenue  growth  through  a mix  of  volume  growth  (8%)  and  price  hikes  (8%) driven by fabric care, dishwashes and personal care. Delayed offtake due  to  a  volatile  season  saw  lower  volume  growth  in  mosquito  repellents.  We  believe  the  focused approach on building up  the detergents and personal-care  sub-categories would drive volumes in coming years and, with the launch of the Ujala liquid sachet, we are upbeat concerning category growth. In addition, we expect  the  continuing  thrust  on  Margo  and  Henko,  backed  by  wider  retail distribution,  to  see  strong  double-digit  volume  growth. The  recent  launch  of Exo liquid may create new sub-categories in dishwashes.

 

Benign raw material prices to improve profitability. Though  the  gross margin contracted 40bps yoy  in 1HFY15 because of higher  input prices,  the recent steep slide in crude oil prices and downward trend in LAB and palm oil may improve it 70-100bps further. We do not expect much increase in A&P spending  as  the management  is  confident  and does not  expect  any pressure from  competition  for  it  to  require  to  spend more  in  any  category  for  this purpose.  The  company  still  enjoys MAT  benefits  and much  lower  interest cost; hence, we have factored in strong, 60%, PAT growth in FY15.

 

Revised estimates. Mounting inflation has led to lower volume growth in the consumer sector in 1HFY15. However, we believe offtake will improve in the second  half  of  the  year.  It  is  evident  that,  because  of  the  delayed  winter, volumes  may  spill  over  to  4QFY15. We  have  revised  our  FY15  and  FY16 revenue, EBITDA and PAT estimates, and introduced FY17 estimates.

 

Our take. We  value  the  stock  at  a  target  price  of  `300. Over  FY15-17  and maintain Buy, we  expect 23%  and 27% CAGRs  in,  respectively,  revenue  and PAT.  At  the  current market  price,  the  stock  quotes  at  26x  FY16e  and  20x FY17e. Risks. Higher raw-material prices and increase in competitive intensity in soaps and detergents.